Floatz logo

Senl-T7

SenL-T7 CAR T Cells for CD7+ T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

Hebei Senlang Biotechnology Inc., Ltd.Cell therapyN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

49 Active assets in the SenL-T7 CAR T Cells for CD7+ T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma cohort.

Asset / SponsorPhaseRating
PREDNISONE TABLETS
Children's Oncology Group
Phase 3BB
Cytosin-Arabinosid
Princess Maxima Center for Pediatric Oncology
Phase 3BB
Cyclophosphamide
Children's Oncology Group
Phase 3BB
ETOPOSIDE
Children's Cancer Group, China
Phase 3BB
Daunorubicin
Children's Oncology Group
Phase 3B

View all 50 →

Same molecule, other indications

Senl-T7 is also rated in:

T-cell non-Hodgkin lymphomaDormant
D
Indicative ·
30 / 100
View asset →
precursor T-cell acute lymphoblastic leukemiaDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →